Ubiquilin 2 (UBQLN2) is an amyotrophic lateral sclerosis-linked molecular chaperone with a prion-like domain that directly engages ubiquitin to triage clients for proteasomal degradation. Dao et al. (2018) now establish that UBQLN2 forms ubiquitin-labile liquids, which may enable UBQLN2 to specifically extract ubiquitylated clients from stress granules for degradation.
In response to stress, cells implement several damage-limitation programs, including the biogenesis of cytoplasmic stress granules (SGs) (Protter and Parker, 2016) . These dynamic membraneless organelles assemble upon inhibition of translation initiation to protect their protein and RNA constituents during deleterious periods. Once stress ebbs, SGs resolve to liberate their proteins and RNAs, which may resume their functions or be degraded. SGs assemble via liquid-liquid phase separation (LLPS) driven by multivalent RNA-RNA, RNAprotein, and protein-protein interactions, including multiple transient contacts between low-complexity, prion-like domains (PrLDs) (March et al., 2016; Protter and Parker, 2016) . Excessive SG assembly or defective SG dissolution after stress is linked with neurodegeneration and may reflect altered phase behavior of SGresident RNA-binding proteins (RBPs) or altered protein-degradation programs (March et al., 2016) . Ubiquilins (UBQLNs) are a family of four (-1, -2, -3, and -4) paralogous molecular chaperones that shuttle ubiquitylated clients to the proteasome for degradation (Hjerpe et al., 2016; Itakura et al., 2016) . Mutations in UBQLN2 or UBQLN4 that impair protein degradation cause amyotrophic lateral sclerosis (ALS) (Deng et al., 2011; Edens et al., 2017) . However, the mechanisms underlying the complete functional repertoire of UBQLNs are not understood. In this issue of Molecular Cell, Castañ eda and coworkers determine that UBQLN2 undergoes LLPS and accumulates in SGs (Dao et al., 2018 (Dao et al., 2018) . Importantly, purified UBQLN2 undergoes reversible LLPS in vitro under relatively physiological conditions, which likely enables UBQLN2 recruitment to SGs in vivo (Dao et al., 2018) . To map the domain requirements for UBQLN2 LLPS, several UBQLN2 deletion constructs were assessed for propensity to form liquid drops. Like other UBQLNs, UBQLN2 harbors a ubiquitinlike domain (UBL; residues 33-103) that associates with proteasomal subunits, two STI1 domains (STI1-I, residues 178-247, and STI1-II, residues 379-462) that interact with molecular chaperones including Hsp70, and a ubiquitin-associating domain (UBA, residues 577-620) that binds to ubiquitin ( Figure 1A ) (Ko et al., 2004) . UBQLN2 also contains a proline-rich region (Pxx) (residues 491-538), which is not found in other UBQLNs. Like UBQLN1, UBQLN2 harbors a PrLD (residues 339-462), which overlaps with STI1-II ( Figure 1A ) (March et al., 2016) . PrLDs are low-complexity domains with a distinctive amino acid composition enriched in glycine and uncharged polar residues such as glutamine, asparagine, tyrosine, and serine, which resemble prion domains that enable various yeast proteins to form prions (March et al., 2016) . PrLDs also drive functional LLPS and deleterious aggregation of several ALS-linked RBPs such as TDP-43 and FUS ( Figure 1A ) (March et al., 2016) . Dao et al. show that UBQLN2 450-624, which includes a portion of the PrLD, STI1-II, Pxx, and UBA domains, is the minimal region necessary for LLPS in vitro and accumulation in SGs in vivo (Dao et al., 2018) . NMR revealed this region to be largely disordered.
Indeed, the UBA domain is folded, but residues 487-580 are intrinsically disordered with backbone relaxation parameters akin to the FUS PrLD (Dao et al., 2018) . However, robust UBQLN2 LLPS under diverse conditions requires the STI1-II portion of the PrLD (Dao et al., 2018) . Deletion of the STI1-II portion of the PrLD or the UBA domain abolishes UBQLN2 LLPS in vitro (Dao et al., 2018) . Thus, several UBQLN2 domains engage in multivalent interactions that elicit LLPS, including major contributions from the STI1-II portion of the PrLD and the UBA domain.
To shuttle ubiquitylated clients to the proteasome, UBQLNs bind ubiquitin and proteasomes directly (Itakura et al., 2016; Ko et al., 2004) . Remarkably, UBQLN2 binding to ubiquitin or polyubiquitin in vitro disrupted UBQLN2 LLPS. Indeed, UBQLN2 LLPS was eliminated by monoubiquitin and K48-linked di-and tetra-ubiquitin chains, a ubiquitin linkage associated with proteasomal degradation. Specific binding of ubiquitin to the UBA domain disrupts multivalent interactions that maintain UBQLN2 liquids (Dao et al., 2018) . Thus, the UBA domain acts as a regulatory switch for UBQLN2 LLPS. As many proteins are ubiquitylated in SGs, UBQLN2 may bind to these ubiquitin chains inside the SG and subsequently disassociate from the SG phase to ferry substrates to the proteasome ( Figure 1B) (Dao et al., 2018) . While Dao et al. focused on K48-linked ubiquitin chains, it will also be interesting to consider other ubiquitin linkages. Given that UBQLNs are also connected to macroautophagy and interact with LC3, an autophagosome marker (Rothenberg et al., 2010) , perhaps UBQLN2 operates in a similar manner with alternative ubiquitin linkages to target clients for autophagy.
Dao et al. advance a model in which UBQLN2 undergoes LLPS driven by multivalent interactions mediated by the STI1-II portion of the PrLD, the Pxx domain, and the UBA domain, which enables SG association in vivo. Upon binding to ubiquitin chains via its UBA domain, UBQLN2 LLPS is disrupted, which elicits release of client-bound UBQLN2 from the SG to enable client degradation by the proteasome ( Figure 1B) . This model provides a mechanism by which UBQLN2 may extract ubiquitylated, ALS-linked RBPs such as TDP-43 and FUS from SGs ( Figure 1B) (Dao et al., 2018) . Moreover, interactions between the UBQLN2 PrLD and PrLDs of TDP-43 and FUS may fluidize SGs and prevent aberrant phase transitions to pathological aggregates (March et al., 2016) . These proposed UBQLN2 activities could have therapeutic utility and are likely corrupted in disease. Indeed, UBQLN2 co-localizes with cytoplasmic inclusions in a wide variety of ALS cases (Deng et al., 2011) . However, these inclusions could be resolved with therapeutic protein disaggregases (Shorter, 2017) . Moving forward, it will be critical to confirm whether UBQLN2 engages ubiquitylated clients inside SGs and removes them from the SG phase for proteasomal degradation in vivo. It will also be important to determine the LLPS propensity of ALSlinked UBQLN2 mutations, the majority of which cluster near the proline-rich Pxx region (Deng et al., 2011) . Finally, it will be enlightening to learn whether ALSlinked UBQLN2 variants are defective in ubiquitylated client extraction from SGs. Deng, H.X., Chen, W., Hong, S.T., Boycott, K.M., Gorrie, G.H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011) . Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211-215.
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